MedWatch

Olympus continues to grow endoscope business

The Japanese medtech firm’s main business area remains on the growth track in its first quarter of 2022/2023, even when adjusting for a big impact from currency effects of a strong US dollar.

Photo: Yuriko Nakao/Reuters/Ritzau Scanpix

Olympus has kept its endoscope business on track in the three months of April, May, and June, making up the Japanese medtech company’s first quarter report for fiscal 2022/2023.

In Q1, Olympus’ Endoscopic Solutions business has grown 17% compared to the same period last year. The company notes a particularly strong performance of its gastrointestinal endoscope products, which reached 18% year-on-year growth.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs